CMV neutralizing antigen binding proteins

A technology that binds proteins and antigens, and is applied in antiviral immunoglobulins, immunoglobulins, antibodies, etc., and can solve problems such as CMV infection

Inactive Publication Date: 2016-05-11
MERCK & CO INC +1
View PDF64 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Although most human CMV infections are asymptomatic, CMV infection can occur in immunocompromised individuals (such as HIV-positive patients, allograft patients, and cancer patients) or those whose immune systems are still underdeveloped (such as newborns). Infections are particularly problematic (Mocarski et al., Cytomegalovirus, Field Virology, 2701-2772, editors: Knipes and Howley, 2007)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CMV neutralizing antigen binding proteins
  • CMV neutralizing antigen binding proteins
  • CMV neutralizing antigen binding proteins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0293] Example 1: Production of a set of rabbit monoclonal antibodies

[0294] The expression of the pentameric gH complex in AD169 was restored and the revertant virus was able to infect MRC-5 and ARPE-19 cells. AD169 (GenBank Accession No. X17403) from ATCC is propagated in MRC-5 cells (Fu et al., 2012, Vaccine 30: 7469-7474; Tang et al., 2011, Vaccine 29: 8350-8356). As described in Fu et al. (2012, Vaccine 30: 7469-7474) and Tang et al. (2011, Vaccine 29: 8350-8356), the revertive virus was generated by continuous passage adaptation of AD169 in culture. The AD169 virus and its revertant isolate were amplified in MRC-5 (ATCC accession number CRL-171) or ARPE-19 (ATCC accession number CRL-2302).

[0295] As determined by antigen titration enzyme-linked immunoassay (EIA), both the revertant virus and its parent AD169 virus contained the same level of gB. Figure 1A Show gB monoclonal antibody B8.6 (IgG 2a κ) and 35.1 (IgG 2a κ) (both developed endogenously) is equivalent to the ...

Embodiment 2

[0298] Example 2: Binding and neutralization profile of anti-CMV monoclonal antibodies

[0299] The ability of the monoclonal antibody to neutralize and bind to the virus and neutralize was determined. The neutralization assay assesses the ability of monoclonal antibodies to prevent entry of viral epithelial cells. The virus binding assay uses ELISA to assess the ability of monoclonal antibodies to bind to virions.

[0300] Briefly, the neutralization assay used is based on counting cells expressing viral immediate early (IE) antigen 24 hours after infection and as previously described (Tang et al., 2011, Vaccine 29: 8350-6). Use Prism 5 (GraphPad Software, SanDiego, CA) to calculate EC from four-parameter curve fitting 50 Value, which is defined as the concentration of antibody required to block 50% of the virus entry.

[0301] In short, the virus binding assay used is an antibody titer enzyme-linked immunoassay (EIA) to determine the relative binding affinity of each monoclonal ...

Embodiment 3

[0312] Example 3: The neutralizing ability of antibodies in epithelial cells is not related to their activity in fibroblasts

[0313] It is known that HIG can block the entry of viruses into fibroblasts, such as MRC-5 cells, and is about 10 to 15 times less effective than blocking the entry of viruses into epithelial cells, namely ARPE-19 cells (Cui et al., 2008, Vaccine 26: 5760-5766). It has been suggested that a different entry mechanism is used for infecting epithelial cells compared to fibroblast viruses (Wang et al., 2007, PNAS 104: 20037-42). Therefore, by measuring the EC in each monoclonal antibody MRC-5 cell 50 Neutralize to evaluate the antibody group (Table 5). Antibody blocks the virus from entering MRC-5 cells (y-axis) compared to the EC of ARPE-19 cells (x-axis) 50 The relationship between the values ​​is shown in image 3 in. All 45 kinds of antibodies can be classified into three groups: the antibodies in group A only neutralize the virus in ARPE-19 cells, the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and / or preventing CMV infections in a patient in need thereof.

Description

Invention field [0001] The present invention relates to anti-CMV antigen binding proteins, including but not limited to monoclonal antibodies. The present invention also relates to the use of the antigen binding protein of the present invention in the diagnosis, treatment and / or prevention of CMV infection. The present invention also includes a composition comprising the antigen binding protein of the present invention. [0002] Cross reference of related applications [0003] This application claims the benefits of U.S. Provisional Application No. 61 / 833,184 filed on June 10, 2013, the content of which is hereby incorporated by reference in its entirety. [0004] Reference to the sequence table submitted electronically [0005] The sequence listing of this application is submitted electronically via EFS-Web as an ASCII formatted sequence listing. The sequence listing file name is "23530-SEQLIST-06JUNE2014.TXT", the creation date is June 6, 2014, and the size is 154KB. The EFS-Web s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/08A61K39/42
CPCC12Q1/70C07K2317/24C07K2317/734C07K2317/76C07K2317/92C07K16/088A61P31/12C07K2317/565
Inventor 傅东明王岱安志强
Owner MERCK & CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap